Core Viewpoint - The article highlights that Qiming Medical's subsidiary Cardiovalve has filed a patent infringement lawsuit against Edwards Lifesciences in the U.S., marking a significant step in the company's legal strategy to protect its intellectual property rights and enhance its competitive position in the global medical device market [1]. Group 1: Company Actions - Qiming Medical's stock price increased by over 14% during trading, with a current price of HKD 3.65 and a trading volume of HKD 26.28 million [1]. - The lawsuit was filed in the Delaware District Court, accusing Edwards of infringing on Cardiovalve's U.S. Patent No. 10,702,385 related to its PASCAL Precision transcatheter valve repair system [1]. Group 2: Industry Implications - Analysts view this legal action as a proactive measure by Qiming Medical following its previous victory in July 2025 regarding the validity of the US'385 patent, emphasizing the importance of intellectual property in the competitive landscape of the medical device industry [1]. - This case is seen as a milestone for Chinese medical device companies in their globalization efforts, showcasing the role of a robust intellectual property system in market competition [1].
启明医疗-B现涨近8% 子公司在美对Edwards重要产品PASCAL提起专利侵权诉讼